Drug Database
TA

tamsulosin

✓ Approved

Ethypharm Corp. · ADRA1A · Small Molecule

What is tamsulosin?

tamsulosin is a small molecule developed by Ethypharm Corp.. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyEthypharm Corp.
Drug ClassSmall Molecule
Molecular TargetADRA1A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ethypharm Corp.

Mechanism of Action

Molecular Targets

tamsulosin acts on 1 molecular target:

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tamsulosin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedSurgical endoscopy2026-09-18

Early removal of urinary catheter before extubation in robotic total mesorectal excision with perioperative tamsulosin.

Andriopoulou Eleni E, Anyfanti Konstantina K, Petropoulou Thalia T

Postoperative urinary retention remains an important concern following total mesorectal excision (TME), resulting in relatively conservative urinary catheter management despite advances in robotic surgery and enhanced recovery after surgery (ERAS) pathways. We evaluated the feasibility of immediate urinary catheter removal before extubation within a structured integrated perioperative pathway incorporating perioperative tamsulosin. A prospective single-centre service evaluation cohort study was conducted between October 2024 and October 2025. Forty-eight consecutive patients undergoing robotic TME for rectal cancer were managed according to a predefined integrated perioperative pathway. All procedures were performed using the da Vinci Xi robotic platform. Tamsulosin 0.4 mg once daily was administered for three days before surgery and three postoperative days. Urinary catheters were removed immediately before extubation. The primary endpoint was successful immediate urinary catheter removal before extubation without the subsequent need for postoperative urinary recatheterisation. Successful immediate urinary catheter removal was defined as spontaneous postoperative voiding without the need for urinary recatheterisation. Failure of the pathway was defined as clinically significant postoperative urinary retention requiring temporary urinary recatheterisation within 72 h after surgery. Secondary outcomes included urinary tract infection, major postoperative morbidity, early mobilisation, readmission and length of stay. Mean age was 61 years and 31 patients (64.6%) were male. Thirty-eight patients (80%) received neoadjuvant treatment, 33 (68.8%) underwent surgery for ultra-low rectal cancer and 40 (83.3%) received a protective ileostomy. Successful immediate urinary catheter removal before extubation without postoperative urinary recatheterisation was achieved in 46 of 48 patients (95.8%). Two patients (4.2%) required temporary urinary recatheterisation because of clinically significant postoperative urinary retention. Recatheterisation occurred in two patients (4.2%; exact 95% confidence interval 0.5-14.3%), both with longstanding benign prostatic hyperplasia receiving chronic medical therapy. No postoperative urinary tract infections, anastomotic leaks, major postoperative complications, readmissions or mortality were observed. Early mobilisation within 24 h was achieved in 45 patients (93.7%), and median postoperative hospital stay was two days. Immediate urinary catheter removal before extubation was feasible in this prospective service evaluation cohort managed within a predefined integrated perioperative pathway. These findings support further prospective comparative evaluation but should not be interpreted as evidence of superiority over conventional catheter management. The concentration of recatheterisation events amongst patients with pre-existing benign prostatic hyperplasia supports further investigation of individualised postoperative urinary management.

PMID 42758176
Read full article →
PubMedUrologiia (Moscow, Russia : 1999)2026-09-15

[Retrograde Intrarenal Surgery: Analysis of Efficacy, Safety and Cost-Effectiveness of drug preparation].

Krutskikh E Yu Y, Dutov S V V, Andronov A S S, Martov A G G

Retrograde intrarenal surgery (RIRS) is the optimal treatment for kidney stones of 5-20 mm, but the success of the intervention depends on providing access through the ureter. Traditional preoperative stenting is accompanied by stent-associated symptoms that worsen patients quality of life. Comprehensive assessment of the efficacy, safety feasibility of using Omnic Ocas for drug preparation of the ureter for RIRS. A prospective single-center study of 58 patients divided into groups: receiving Omnic Ocas 0.4 mg/day (n=29) and prestenting group (n=29). Intra- and postoperative parameters were evaluated. Additionally, a systematic review of 10 RCTs (n=1624) was performed. In the local study, the frequency of successful ureteral access sheath installation was comparable between groups (87% vs 92%, p>0.05). The Omnic Ocas group showed significantly better pain scores (3.2+/-1.1 vs 5.9+/-1.6 points, p<0.001), need for analgesics and quality of life according to the USSQ questionnaire (22.5+/-5.7 vs 34.8+/-7.3 points, p<0.001). Systematic review confirmed the advantages of tamsulosin over no preparation and comparable efficacy with prestenting with better tolerability. Drug preparation with Omnic Ocas is not inferior to prestenting in efficacy, but superior in tolerability and economic feasibility, being a preferred alternative.

PMID 42742548
Read full article →
PubMedJournal of clinical medicine2026-09-15

Alpha-Adrenoceptor Blockade as a Novel Pathway Toward Non-Hormonal Male Contraception: A Mechanistic and Clinical Evidence Review.

Roztocka Alicja A, Osiński Patryk P, Car Halina H, Nazarko Natalia N et al.

Alpha-1 adrenergic receptor antagonists are widely used in the management of lower urinary tract symptoms, where they can induce ejaculatory dysfunction as a pharmacodynamic effect, particularly with α1A-selective agents. This observation has led to growing interest in their potential role as non-hormonal male contraceptives. This narrative review evaluates current clinical and preclinical evidence regarding the impact of α-blockers on the ejaculatory mechanism, with a focus on their potential application in male contraception. Both human and animal data were examined to contextualize the mechanistic basis for contraceptive potential. Evidence from clinical and pharmacological studies indicates that inhibition of α1-adrenoceptor-mediated smooth-muscle contraction in tissues involved in seminal emission, including the vas deferens, seminal vesicles, and prostate, can impair the emission phase of ejaculation. Agents such as tamsulosin and silodosin have been reported to induce anejaculation or markedly reduce semen volume, providing pharmacodynamic evidence of impaired seminal emission; however, these effects should not be considered equivalent to demonstrated contraceptive efficacy. Prospective clinical evidence currently includes one prospective pilot study and one randomized placebo-controlled clinical trial evaluating silodosin as a potential reversible non-hormonal male contraceptive. The prospective evidence includes marked and progressive suppression of sperm output and semen volume with repeated silodosin administration; at week 12, 94% of participants achieved a total sperm count ≤ 1 × 106 per ejaculate, while the observed pregnancy incidence was 4% versus 17% with placebo. However, the available evidence remains insufficient to establish reliable contraceptive effectiveness for individual sexual exposures. Safety considerations, including cardiovascular effects and sexual dysfunction, also remain insufficiently characterized in healthy men. α1-adrenoceptor antagonists represent a biologically plausible pharmacologic strategy for male non-hormonal contraception by interfering with seminal emission and sperm delivery without directly suppressing spermatogenesis. Further pharmacokinetic-pharmacodynamic studies and rigorously designed multicentre clinical trials are required to determine the optimal dosing strategy, completeness and consistency of seminal emission suppression, contraceptive effectiveness, safety, acceptability, and reversibility of this approach.

PMID 42739649
Read full article →
PubMedPhytomedicine : international journal of phytotherapy and phytopharmacology2026-09-13

Efficacy and safety of Qianlieshutong Capsules in the treatment for Type III prostatitis: A post-marketing, multicenter, randomized, double-blind, single-dummy, active-controlled, parallel-group clinical trial.

Hou Huimin H, Jiang Yuxiao Y, Chen Yongming Y, Zhang Fanguo F et al.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS, NIH category III) remains a challenging condition with no universally accepted treatment. Although alpha-blockers and antibiotics are commonly used, their efficacy is inconsistent. In this study, we aimed to evaluate the efficacy and safety of Qianlieshutong Capsules (QLSTCs, a standardized traditional Chinese medicine) combined with tamsulosin versus tamsulosin alone in patients with CP/CPPS. In this post-marketing, multicenter, randomized, double-blind, single-dummy clinical trial, 240 male patients aged 18-50 years diagnosed with CP/CPPS were randomly assigned (1:1) to receive either QLSTCs (0.4 g/capsule, 3 capsules, three times daily) plus tamsulosin (0.2 mg nightly) or a matching placebo plus tamsulosin for 8 weeks. The primary endpoint was the change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score from baseline to week 8. Secondary outcomes included changes in the NIH-CPSI score at week 4, domain-specific scores (pain, urinary symptoms, quality of life), and treatment response rates. Safety was assessed through adverse events (AEs), laboratory tests, vital signs, and ECG. Of the 240 randomized patients, baseline characteristics were comparable. At week 8, the combination group showed a significantly greater reduction in the total NIH-CPSI score than the control group (14.30 ± 0.53 vs. 10.60 ± 0.54; mean difference = 3.70, 95% CI: 2.36-5.04; P < 0.0001). The effective response rate and marked improvement rate were significantly higher in the combination group. Improvements were also significant in all NIH-CPSI domains at week 8. AE incidences were low and comparable between groups (10.00% vs. 9.24%), with no serious AEs reported. The combination of QLSTCs and tamsulosin is a safe and more effective treatment than tamsulosin alone for CP/CPPS, offering superior symptom relief, particularly in pain, urinary symptoms, and quality of life. This approach may serve as a promising multimodal therapeutic option in clinical practice.

PMID 42731448
Read full article →
PubMedArchivos espanoles de urologia2026-09-03

Effect of Tamsulosin Combined With Flexible Ureteroscopic Holmium Laser Lithotripsy on Renal Function and Postoperative Inflammatory Response in Patients With Renal Calculi.

Jiang Xiaoxiang X, Ying Lihong L

To investigate the association between perioperative tamsulosin use and outcomes of flexible ureteroscopic holmium laser lithotripsy (FURL). This retrospective cohort study was performed on 122 patients who underwent FURL at Cixi People's Hospital, Wenzhou Medical University. Patients were divided into an observation group (perioperative tamsulosin + FURL, n = 62) and a control group (FURL alone, n = 60) according to routine clinical protocols and patient preference. Operation time, stone clearance rate at 4 weeks postoperatively, renal function indicators, inflammatory markers, and complication rates were compared between the two groups. Compared with the control group, the observation group had shorter operation time (51.34 ± 9.28 vs. 58.62 ± 10.35 min, p < 0.001), shorter postoperative hospital stay (3.62±1.05 vs. 4.85±1.23 days, p < 0.001), and a higher stone clearance rate (93.55% vs. 75.00%, p = 0.005). On postoperative day 1 and at week 1, renal function indicators were significantly lower in the observation group (all p < 0.05). Serum inflammatory marker levels on postoperative days 1 and 3 were also significantly lower in the observation group (all p < 0.001). The total complication rate was lower in the observation group (8.06% vs. 21.66%, p = 0.036). In this retrospective study, perioperative tamsulosin combined with FURL was associated with shorter operation times, higher stone clearance, and lower renal function, inflammatory, and complication markers. However, due to potential selection bias, these associations require confirmation via prospective randomized controlled trials.

PMID 42684289
Read full article →
PubMedFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026-09-03

ASIV Attenuates Cisplatin-Induced Proximal Tubular Injury by Enhancing Mitochondrial Biogenesis and Mitophagy Through the ADRA1A/AMPK/FOXO3A Pathway.

Wang Meng M, Peng Wang W, Wei Yani Y, Yu Hangxing H et al.

Cisplatin causes nephrotoxicity by accumulating in renal tubular epithelial cells (RTECs). Astragaloside IV (ASIV) shows renoprotective potential, but its mechanisms remain poorly understood. Cisplatin induced nephrotoxicity was established in 8-week-old male C57BL/6 mice via intraperitoneal administration of cisplatin at 20 mg/kg for 48 h. For in vitro studies, HK-2 human proximal tubular epithelial cells were exposed to 50 μM cisplatin for 24 h. Multi-omics approaches were employed to identify novel mechanisms by which ASIV ameliorates cisplatin-induced proximal tubular injury. ASIV markedly reduced serum creatinine and urea nitrogen levels in mice, and ameliorated cisplatin-induced proximal tubular injury both in vivo and in vitro. Moreover, ASIV restored mitochondrial damage, upregulated protein expression of PGC-1α, TOMM20, and PINK1 in RTECs. Mechanistically, RNA-seq and scRNA-seq revealed that cisplatin predominantly affected ADRA1A-mediated mitochondrial biogenesis and mitophagy in proximal tubular cells, accompanied by suppression of the AMPK/FOXO3A pathway. Notably, ASIV upregulated ADRA1A expression, thereby facilitating AMPK and FOXO3A phosphorylation and consequently enhancing mitochondrial biogenesis and mitophagy. Furthermore, dabuzalgron (a selective ADRA1A agonist) recapitulated the protective effects of ASIV. In contrast, the renoprotective action of ASIV against cisplatin-induced proximal tubular injury was largely abrogated by the ADRA1A antagonist tamsulosin in vivo and by ADRA1A-specific siRNA in vitro. These findings identify ASIV as a highly promising renoprotective agent that upregulates ADRA1A expression and activates the AMPK/FOXO3A axis to enhance mitochondrial biogenesis and mitophagy, thereby counteracting cisplatin-induced proximal tubular injury.

PMID 42687819
Read full article →

+2306 more articles available with a free account

Sign up free to view all articles →

Ask about tamsulosin